한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제28권2호
  • /
  • Pages.117-123
  • /
  • 2018
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

건강보험 청구자료를 이용한 전립선염 환자의 의료 이용 및 항생제 처방 현황

Medical Utilization and Antibiotics Use of Prostatitis Patients in Korea

  • Lee, Boram (Graduate School of Public Health, Seoul National University) ;
  • Choi, Yoon Jung (Health Insurance Review and Assessment Service) ;
  • Choi, Younsong (Health Insurance Review and Assessment Service) ;
  • Kong, Nayoung (Health Insurance Review and Assessment Service) ;
  • Choi, Minsun (Health Insurance Review and Assessment Service)
  • 투고 : 2017.11.08
  • 심사 : 2018.04.11
  • 발행 : 2018.06.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Prostatitis, one of the most common diseases of the prostate, is a complex disease with various clinical features. This study aims to analyze the utilization and prescribing patterns of antibiotics in Korean patients with prostatitis between 2008 and 2015. Methods: We used the National Health Insurance Database complied from the Health Insurance Review and Assessment Service (HIRA). The outcomes included the number of claims, number of patients, medical cost, and length of stay for each year. In addition, the prescribing patterns of antibiotics, including fluoroquinolone, and low-dose use of ciprofloxacin and levofloxacin were investigated. Results: The total number of patients and medical cost increased by 9.5% and 51.7% from 2008 to 2015, respectively. Most prostatitis patients were classified as chronic prostatitis patients. The prescribing proportion of antibiotics for chronic prostatitis outpatients decreased from 71.0% to 66.9% from 2008 to 2015, and fluoroquinolone accounted for more than half of the total antibiotics. Over 80% of prescription of levofloxacin and ciprofloxacin was identified to be for low-dose use. Conclusion: Most of the patients with prostatitis experienced pain relief and condition improvement after antibiotic treatment; however, chronic prostatitis and chronic pelvic pain syndrome recur easily. Therefore, active disease management and further studies are needed to enhance our understanding of effective treatment for prostatitis.

키워드

참고문헌

  1. Chung H. Chronic Prostatitis/Chronic Pelvic Pain Syndrome: What Are the Starting and Worsening Factors? Korean J Urogenit Tract Infect Inflamm 2013;8(1):7-12. https://doi.org/10.14777/kjutii.2013.8.1.7
  2. Kim KS, Lee SW. Manegement of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). Korean J Urol Oncol 2014;12(1):23-8.
  3. Korean Urological Association. Available from http://www.urology.or.kr./health/sub07.html. Accessed September 10, 2017.
  4. Krieger JN, Lee SWH, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008;31(Suppl 1):S85-90.
  5. Mehik A, Hellstrom P, Lukkarinen O, et al. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int 2000;86:443-8. https://doi.org/10.1046/j.1464-410X.2000.00836.x
  6. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167(3):1363-6. https://doi.org/10.1016/S0022-5347(05)65301-3
  7. Krieger JN, Nyberg LJ, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7. https://doi.org/10.1001/jama.282.3.236
  8. Cho IR. The Present and Future of Prostatitis. Investig Clin Urol 2008;49(6):475-89.
  9. Nickel JC. Prostatitis. Can Urol Assoc J 2011;5(5):306-15.
  10. Nickel JC, Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. Urology 2005;66(1):2-8. https://doi.org/10.1016/j.urology.2004.12.028
  11. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis. Infect Chemother 2011;43(1):1-25. https://doi.org/10.3947/ic.2011.43.1.1
  12. Johansen TB, Gruneberg RN, Guibert J, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34(6):457-66. https://doi.org/10.1159/000019784
  13. Tillotson GS. Quinolones: structure-activity relationships and future predictions. J Med Microbiol 1996;44(5):320-4. https://doi.org/10.1099/00222615-44-5-320
  14. North DS, Fish DN, Redington JJ. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy 1998;18(5):915-35.
  15. Tugcu V, Tasci AI, Fazlioglu A, et al. A placebo-controlled comparison of the efficiency of triple-and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007;51(4):1113-8. https://doi.org/10.1016/j.eururo.2006.09.036
  16. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2010;106(9):1252-63. https://doi.org/10.1111/j.1464-410X.2010.09701.x
  17. Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011;305(1):78-86. https://doi.org/10.1001/jama.2010.1913
  18. Shoskes DA, Nickel JC. Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World J Urol 2013;31:755-60. https://doi.org/10.1007/s00345-013-1075-6
  19. Perletti G, Marras E, Wagenlehner FME, et al. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013;8;CD009071.
  20. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2016. Available from https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/. Accessed August 24, 2017.
  21. Collins MM, Pontari MA, O'Leary MP, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001;16(10):656-62. https://doi.org/10.1111/j.1525-1497.2001.01223.x
  22. National Health Insurance Service. Available from http://www.nhis.or.kr/bbs7/boards/B0039/14075. Accessed February 24, 2017.
  23. Cho IR. Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Guidelines for Antibiotic Therapy. Korean J UTII 2006;1(1):39-44.
  24. Health Insurance Review and Assessment Service. Available from http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=6474#none. Accessed February 24, 2018.
  25. Ministry of Health and Welfare. Available from http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=342824. Accessed February 24, 2018.
  26. Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician 2010;82(4):397-406.
  27. Snow DC, Shoskes DA. Pharmacotherapy of prostatitis. Expert Opin Pharmacother 2010;11(14):2319-30. https://doi.org/10.1517/14656566.2010.495946
  28. Rees J, Abrahams M, Doble A, et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int 2015;116(4):509-25. https://doi.org/10.1111/bju.13101
  29. Expert Working Group on Canadian Guidelines for Sexually Transmitted Infections. Prostatitis. In:Canadian guidelines on sexually transmitted infections Section 4 - Management and Treatment of Specific Syndromes. Public Health Agency of Canada. Available from http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-4-5-eng.php. Accessed August 24, 2017.
  30. Dickson G. Prostatitis: diagnosis and treatment. Aust Fam Physician 2013;42(4):216.
  31. Jin HQ, Sohng IH, Byun YM, et al. Symptomatic Analysis of Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Korean Continence Soc 2006;10:49-54. https://doi.org/10.5213/jkcs.2006.10.1.49